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Abstract: Indolic compounds have attracted a lot of attention due to their interesting 
biological properties. The present study was performed to evaluate the subacute toxicity 
and anti-ulcer activity of BClHC against ethanol-induced gastric ulcers. Experimental 
animal groups were orally pre-treated with different doses of BClHC (50, 100, 200 and  
400 mg/kg) in 10% Tween 20 solution (vehicle). Blank and ulcer control groups were  
pre-treated with vehicle. The positive group was orally pretreated with 20 mg/kg 
omeprazole. After one hour, all groups received absolute ethanol (5 mL/kg) to generate 
gastric mucosal injury except the blank control group which was administered the vehicle 
solution. After an additional hour, all rats were sacrificed, and the ulcer areas of the gastric 
walls determined. Grossly, the ulcer control group exhibited severe mucosal injury, 
whereas pre-treatment with either derivative or omeprazole resulted in significant 
protection of gastric mucosal injury. Flattening of gastric mucosal folds was also observed  
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in rats pretreated with BClHC. Histological studies of the gastric wall of ulcer control 
group revealed severe damage of gastric mucosa, along with edema and leucocytes 
infiltration of the submucosal layer compared to rats pre-treated with either BClHC or 
omeprazole where there were marked gastric protection along with reduction or absence  
of edema and leucocytes infiltration of the submucosal layer. Subacute toxicity study  
with a higher dose of derivative (5 g/kg) did not manifest any toxicological signs in  
rats. In conclusions, the present finding suggests that benzyl N'-(5-chloroindol-3-
ylmethylidene)hydrazinecarbodithioate promotes ulcer protection as ascertained by the 
comparative decreases in ulcer areas, reduction of edema and leucocytes infiltration of the 
submucosal layer. 
Keywords: indole; benzyl N'-(5-chloroindol-3-ylmethylidene)hydrazinecarbodithioate; 
histology; omeprazole; gastric ulcer 
 
1. Introduction 
Indolic compounds have attracted a lot of attention due to their interesting biological properties. 
Antioxidant [1,2], anticancer [3,4], antiviral [5], antiulcer [6] and wound healing activities [7] can be 
mentioned as some of the significant activities associated with the indole nucleus. Likewise, 
derivatives of dithiocarbazic acid have been proven to exhibit a wide variety of bioactivities such as 
antimicrobial [8], anticancer [9], antibacterial and antifungal [10] properties. Through our ongoing 
efforts to develop new potent wound healing agents, we recently reported the wound healing potential 
of the Schiff base formed from indole-3-carboxaldehyde and S-benzyldithiocarbazate [11]. The present 
findings suggest that BClHC promotes ulcer protection as ascertained grossly by significant reduction 
of ulcer area, and histologically by comparative decreases in ulcer areas, reduction or absence of 
edema and leucocytes infiltration of the submucosal layer compared to the ulcer control group. 
2. Results and Discussion 
2.1. Subacute Toxicity 
Study in which the animals were treated with doses of 2 and 5 g/kg of BClHC did not manifest any 
significant abnormal signs and behavioral changes. There was no mortality with these oral doses at the 
end of 14 days of observation (Figure 1). The serum biochemistry parameters (liver function tests) of 
the BClHC treated rats showed no significant changes compared to the control normal rats. From these 
results it is concluded that this compound has no subacute toxicity and the oral lethal dose for the male 
and female rats is in excess of 5 g/kg of BClHC (Tables 1 and 2). 
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Figure 1. Histological sections of liver and kidney in subacute toxicity test (A) liver of rats 
treated with vehicle (10% Tween 20, 5 mL/kg) showing normal structural appearance; (B) 
kidney of rats treated with vehicle (10% Tween 20, 5 mL/kg) showing normal structural 
appearance; (C) Liver of rats treated with 2 g/kg of BClHC showing normal structural 
appearance; (D) Kidney of rats treated with 2 g/kg of BClHC showing normal structural 
appearance; (E) Liver of rats treated with 5 g/kg of BClHC showing normal structural 
appearance; (F) kidney of rats treated with 5 g/kg of BClHC showing normal structural 
appearance. 
(A) (B) 
 
(C) (D) 
 
(E) (F) 
 
Table 1. Renal function test of rats in acute toxicity study of BClHC compound. 
Animal 
Groups 
Renal Function Test of BClHC 
Sodium 
(mmol/L)
Pottasium 
(mmol/L) 
Chloride 
(mmol/L)
CO2 
(mmol/L)
Anion gap 
(mmol/L) 
Urea 
(mmol/L) 
Creatinine
(µmol/L) 
Normal 
control 
138.34 ± 
0.62 
5.12 ± 
0.17 
103.42 ± 
0.76 
22.70 ± 
0.73 
19.34 ± 
0.76 
5.68 ± 
0.36 
50.78 ± 
1.30 
L. D 
(2 g/kg) 
138.42 ± 
0.74 
5.25 ± 
0.18 
102.67 ± 
1.06 
20.63 ± 
0.69 
19.67 ± 
1.08 
5.19± 
0.34 
49.12 ± 
0.85 
H. D 
(5 g/kg) 
138.29 ± 
0.67 
4.94 ± 
0.20 
102.50 ± 
0.70 
22.29 ± 
0.72 
18.58 ± 
0.61 
5.78 ± 
0.30 
49.25 ± 
1.39 
Values expressed as means ± S.E.M. There are no significant differences between groups. 
Significant values at p < 0.05. 
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Table 2. Liver function test of rats in acute toxicity study of BClHC compound. 
Animal 
Groups 
Liver Function test of BClHC 
Total 
protein 
(g/L) 
Albumin 
(g/L) 
Globulin 
(g/L) 
Total 
bilirubin 
(µmol/L) 
Conjugated 
bilirubin 
(µmol/L) 
AP 
(IU/L) 
ALT 
(IU/L) 
AST 
(IU/L) 
G-Glutaml. 
Transferase 
(IU/L) 
Normal 
control 
70.34 ± 
1.25 
11.58 ± 
0.63 
59.17 ± 
1.23 
2.04 ± 
0.20 
1.25 ±  
0.25 
135.08 ± 
9.27 
53.00 ± 
1.97 
152.31 ± 
5.14 
4.96 ±  
0.71 
L.D 
(2 g/kg) 
70.25 ± 
0.85 
11.92 ± 
0.41 
58.59 ± 
0.51 
2.21 ± 
0.20 
1.42 ±  
0.16 
134.17 ± 
4.77 
50.92 ± 
1.12 
157.59 ± 
2.11 
4.88 ±  
0.85 
H D 
(5 g/kg) 
70.42 ± 
0.94 
12.17 ± 
0.68 
58.67 ± 
0.85 
1.82 ± 
0.23 
1.59 ±  
0.06 
135.08 ± 
3.86 
51.84 ± 
3.57 
153.84 ± 
6.64 
5.33 ±  
0.71 
Values expressed as mean ± S.E.M. There are no significant differences between groups. Significant value  
at p < 0.05; T. Prot: Total protein; TB: Total bilirubin; CB: Conjugated bilirubin; AP: Alkaline phosphatase; 
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AG: anion gap; Crt: creatinine. 
2.2. Gross Evaluation of Gastric Lesions 
Rats pre-treated with either omeprazole or various concentrations of BClHC before being given 
absolute alcohol had significantly reduced areas of gastric ulcer formation compared to rats pre-treated 
with vehicle, 10% Tween 20 solution (ulcer group) (Table 3 and Figure 2). Moreover, BClHC 
administration significantly suppressed the formation of the ulcers and it was interesting to note the 
flattening of gastric mucosal folds in rats pretreated with this compound. It was also observed that 
protection of gastric mucosa was more prominent in rats pre-treated with 400 mg/kg BClHC  
(Table 3). In addition, ethanol-induced mucosal damage was significantly and dose-dependently 
reduced in size and severity by pre-treating the animals with BClHC (the significant inhibition of 
gastric ulcers in pretreatment with BClHC was compared with omeprazole, which is a standard drug 
used for curing gastric ulcers). 
Table 3. Observed ulcer area and inhibition percentage of BClHC in rats. Values are 
means ± SEM of six animals. 
Group Pretreatment 5 mL/Kg 
Ulcer (mm2) 
X ± SEM Inhibition % 
1 10% Tween 20 922.00 ± 7.63 a 0.00 
2 Omeprazole 215.00 ± 4.54 b 76.68% 
3 50 mg/Kg 54.00 ± 3.08 c 94.14% 
4 100 mg/Kg 38.40 ± 2.400 cd 95.84% 
5 200 mg/Kg 22.80 ± 2.89 de 97.53% 
6 400 mg/Kg 12.00 ± 2.400 ef 98.70% 
All values are expressed as means ± standard error mean. Means with different 
superscripts are significantly different. The mean difference is significant at the  
p < 0.05 level. 
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Figure 2. Gross appearance of the gastric mucosa in rat, (A) pre-treated with vehicle 0.2 mL 
of 10% Tween 20 (ulcer control). Severe injuries are seen in the gastric mucosa 
(arrow).Absolute ethanol produced extensive visible hemorrhagic necrosis of gastric 
mucosa; (B) Rats pre-treated with omeprazole (20 mg/Kg). Injuries to the gastric mucosa 
are milder (arrow) compared to the injuries seen in the ulcer control rats; (C) Rats  
pre-treated with BClHC (100 mg/Kg). Mild injuries to the gastric mucosa can be seen 
showing the beginning of gastric mucosa flattening; (D) Rats pre-treated with BClHC  
(200 mg/Kg). Very mild injuries to the gastric mucosa can be seen, showing the flattening 
of gastric mucosa, (E) Rats pre-treated with BClHC alone (400 mg/Kg). No injuries to the 
gastric mucosa are seen, but the flattening of gastric mucosa can been seen. 
(A) (B) 
 
(C) (D) 
 
(E) 
2.3. Histological Evaluation of Gastric Lesions 
Microscopic observations of ethanol-induced gastric lesions in ulcer control rats (pre-treated with 
vehicle, 10% Tween 20), showed marked extensive damage to the gastric mucosa, and edema and 
leucocytes infiltration of the submucosal layer (Figure 3A). Rats that were pre-treated with either 
BClHC or omeprazole each had comparatively better protection of the gastric mucosa as seen by the 
reduction in ulcer area, reduced submucosal edema and absence of leucocytes infiltration (Figure 3B,C). 
The BClHC has been shown to exert the cytoprotective effects in a dose-dependent manner. 
Ulcer Ulcer
No ulcer 
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Figure 3. Histological sections of the ethanol-induced gastric mucosal damage in rats 
(H&E stain 10×). (A) Rats pre-treated with 5 mL/Kg of 10% Tween 20 solution (ulcer 
control). There is severe disruption to the surface epithelium, and edema of the submucosal 
layer with leucocytes infiltration. (B) Rats pre-treated with 20 mg/kg of omeprazole. There 
is mild disruption to the surface epithelium with no edema and no leucocytes infiltration of 
the submucosal layer. (C) Rats pre-treated with 200 mg/kg of BClHC. There is very mild 
disruption to the surface epithelium with no edema and no leucocytes infiltration of the 
submucosal layer. (D) Rats pre-treated with 400 mg/kg of BClHC. There is no disruption 
to the surface epithelium with the absence of edema and leucocytes infiltration of the 
submucosal layer. 
(A) (B) 
 
(C) (D) 
 
2.4. Periodic Acid Schiff (PAS) of Mucosal Glycoprotein’s 
Increased the PAS staining (magenta color) of gastric mucosa of treated animals with BClHC 
comparison to ulcer control group indicating increase in glycoprotein content of gastric mucosa. 
BClHC-treated group reserved the decrease in PAS staining induced by ethanol (Figure 4). 
Edema 
Ulcer 
Necroti
c lesion  
Leucocytes 
infiltration 
Fewer lesions  No ulcer
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Figure 4. The effect of BClHC on gastric tissue glycoprotein-PAS staining in ethanol-induced 
gastric ulcer in rats (PAS stain 20×). (A) Normal control group; (B) Ulcer control group; (C) 
BClHC-treated group with 50 mg/kg; (D) BClHC-treated group with 400 mg/kg. 
(A) (B) 
(C) (D) 
This study investigated the effects of BClHC on gastric ulcer compared to omeprazole, a  
drug whose ulcer healing effects have been extensively studied. The present compound (BClHC) is a 
hybrid molecule, obtained by condensation of two pharmacophores: indole carbaldehyde and  
S-benzyl-dithiocarbazate. Schiff bases derived by condensation of heterocyclic aldehydes with  
S-benzyl-dithiocarbazate have been shown to exhibit significant biological activities. It has been 
proposed that the biological activity of these Schiff bases may come from their interaction with 
potential donors of biological heterocyclic in vivo. In many cases, the pharmacological activity has 
been found to be highly dependent on the identity of the donor sequence of the ligands, as different 
ligands show widely different biological activities, although they may vary only slightly in their 
molecular structure.  
BClHC was found to have a protective effect on the gastric mucosa similar to that of omeprazole. 
Omeprazole and BClHC were both found to have protective effects compared to the ulcer control 
group (10% Tween 20). This suggests that BClHC does indeed have a potential anti-ulcer effect.  
BClHC has been shown to display anti-cancer activity [9] and it is speculated that the  
gastro-protective effect exerted by BClHC could be attributed to this anti-cancer activity, which could 
also be a key factor in the prevention of gastric ulcer as reported by Das and Livingstone [12]. 
Microbial infection of wounds delays healing [13] and causes a more pronounced subacute 
inflammatory reactions [14], which can lead to further tissue injury and damage. It is also important to 
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mention that BCIHC has demonstrated an antimicrobial activity [8], that may partly contribute to the 
wound healing effect by eliminating infections, thus allowing the natural tissue repair processes to 
start. It also suggests that the BCIHC may also play a useful role in accelerating the healing of old 
wounds by eradicating already established infections. The antimicrobial activity of honey and the 
essential oil of Melaleuca alternifolia are believed to underlie their usefulness as alternative therapy in 
wound healing [15,16]. 
The main cause of gastric ulcer is destruction of the gastric mucosal barrier consisting of the surface 
epithelium and mucosal coat. This destruction may be due to an increase in gastric acid secretion, 
decrease in mucus production or decrease in mucosal blood flow [17]. Ethanol administration is a 
simple method used for inducing gastric ulcers in experimental rats and leads to severe gastric mucosal 
injury. Ethanol shows its harmful effects either through direct generation of reactive metabolites, 
including free radical species that react with most of the cell components, changing their structures and 
functions, or promote enhanced oxidative damage [18,19]. Ethanol damage to the gastrointestinal 
mucosa with microvascular injury, disruption of the vascular endothelium resulting in increased 
vascular permeability, edema formation and epithelial lifting [20]. It produces necrotic lesions in the 
gastric mucosa by its direct toxic effect, reducing the secretion of bicarbonates and production of 
mucus [21]. Ethanol is metabolized in the body releasing superoxide an ion and hydroperoxyl free 
radicals which are involved in the mechanism of subacute and chronic ulceration in the gastric  
mucosa [22]. Observed that administration of ethanol caused disturbances in gastric secretion, damage 
to the gastric mucosa, alterations in permeability, gastric mucus depletion and free-radical production.  
Oxidative stress plays a major role in the pathogenesis of various diseases including gastric ulcer. 
Indolic compounds have shown to possess antioxidant activity [23,24] which may mediate the 
protection of gastric mucosa. Antioxidants are important inhibitors of lipid per-oxidation, not only for 
food protection but also as a defense mechanism of living cells against oxidative damage [25]. 
Antioxidants have been reported to play a significant role in preventing gastric ulcers. It appears that 
antioxidant may be an important contributory factor in the protection of gastric mucosa [26]. Studies 
have shown that antioxidant significantly strength gastric walls and protect tissues from oxidative 
damage [27]. The result of the present study also revealed protection of gastric mucosa and inhibition 
of leucocytes infiltration of gastric wall in rats pretreated with BClHC. Similarly, Kobayashi et al. [28] 
reported that teprenone exerts a protective effect against mucosal lesions through inhibition of 
neutrophil infiltration in the ulcerated gastric tissue and [29] demonstrated that the reduction of 
neutrophil infiltration into ulcerated gastric tissue promotes the healing of gastric ulcers in rats [30], 
showed that oral administration of compound before ethanol administration significantly decreased 
neutrophil infiltration of gastric mucosa. Absolute alcohol would extensively damage the gastric 
mucosa leading to increased neutrophil infiltration into the gastric mucosa. Oxygen free radicals 
derived from infiltrated neutrophils in ulcerated gastric tissues have inhibitory effect on gastric ulcers 
healing in rats [31]. Neutrophils mediate lipid per-oxidation through the production of superoxide 
anions [32]. Neutrophils are a major source of inflammatory mediators and can release potent reactive 
oxygen species such as superoxide, hydrogen peroxide and myeloperoxidase derived oxidants. These 
reactive oxygen species are highly cytotoxic and can induce tissue damage [30]. Furthermore, 
neutrophil accumulation in gastric mucosa has been shown to induce microcirculatory abnormalities [33]. 
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Suppression of neutrophils infiltration during inflammation was found to enhance gastric ulcer  
healing [34]. 
In the current study, we observed flattening of the mucosal folds, which suggests that the 
gastroprotective effect of BClHC might be due to a decrease in gastric motility. It is reported that 
changes in the gastric motility may play a role in the development and prevention of experimental 
gastric lesions [35,36]. Relaxation of circular muscles may protect the gastric mucosa through 
flattening of the folds. This will increase the mucosal area exposed to necrotizing agents and reduce 
the volume of the gastric irritants on regal crest [37]. Ethanol produces a marked contraction of the 
circular muscles of rat fundic strip, and such a contraction can lead to mucosal compression at the site 
of the greatest mechanical stress, at the crests of mucosal folds leading to necrosis and ulceration [38]. 
The subacute toxicity profile of BClHC could be considered favorable, judging for the absence of 
adverse clinical manifestations in experimental animals after two week of observation. It is concluded 
that subacute toxicity study with a higher dose of BClHC (5 g/kg) did not manifest any toxicological 
signs in rats and that the oral lethal dose for male and female albinos Wistar rats is in excess of 5 g/kg. 
Based on this subacute toxicity test, BClHC was found safe. In conclusion, BClHC could significantly 
protect the gastric mucosa against ethanol-induced injury. Such protection was shown to be dose 
dependent as ascertained by the reduction or inhibition of ulcer areas in the gastric wall as well as the 
reduction or inhibition of edema and leucocytes infiltration of submucosal layers, and protection was 
most prominent at a dose of 400 mg/kg BClHC. 
3. Experimental 
3.1. Omeprazole 
Omeprazole is a proton pump inhibitor which has been widely used as acid inhibitor agents for the 
treatment of disorders related to gastric acid secretion for the last 15 years [39]. Omeprazole is a 
substituted benzimidazole that inhibits acid secretion by acting on the hydrogen-potassium exchanger 
(H+/K+-ATPase) for the apical plasma membrane of the gastric mucosa [40]. Omeprazole is highly 
selective for the proton pump and undergo catalyzed conversion into active form within the acid 
forming space. The active inhibitors react with SH (thiol) group of the proton pump, resulting in 
inhibition of acid formation [41]. In this study, omeprazole was used as the reference anti-ulcer drug, 
and was obtained from the University Malaya Medical Centre (UMMC) Pharmacy. The drug was 
dissolved in 10% Tween 20 solution and administered orally to the rats in doses of 20 mg/kg body 
weight (5 mL/kg) [42]. 
3.2. Synthesis of Benzyl N'-(5-Chloro-indol-3-ylmethylidene)hydrazinecarbodithioate 
S-benzyldithiocarbazate was prepared as reported previously [43]. Briefly, 5-chloroindole-3-
carbaldehyde (5.39 g, 0.03 mol) and S-benzyl dithiocarbazate (5.94 g, 0.03 mol) were heated in 
ethanol (300 mL) for 3 h. The solution was set aside for few hours whereupon a yellow precipitate 
formed. This precipitate was filtered off, washed with cold ethanol and dried over silica gel; yield,  
9.8 g (91%) (Figure 5).  
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Figure 5. Benzyl N'-(5-chloroindol-3-ylmethylidene)hydrazinecarbodithioate. 
S N
H
S
N
NH
Cl
 
3.3. Experimental Animals 
Adult male albino Wistar rats were obtained from the Animal House, Faculty of Medicine, 
University of Malaya, Kuala Lumpur, Malaysia. All the animals used for study has an ethical clearance 
from the animal user’s Committee of the Faculty of Medicine, University Malay (Ethics No. PM 
28/9/2008 MAA (R)). The rats weighed between 200–220 g. They were fasted for 48 hours before the  
experiment [44], but were allowed free access drinking water until 2 hours before the experiment. 
During the fasting period, the rats were placed individually in separate cages with wide-mesh wire 
bottoms. On the day of the experiment, the rats were randomly divided into seven groups of six rats 
each. Throughout the experiments, all animals received human care according to the criteria outlined 
in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of 
Sciences and published by the U.S. National Institutes of Health [45]. 
3.4. Subacute Toxicity Studies 
The subacute toxic study was used to determine a safe dose for the BClHC. Thirty six albino Wistar 
rats (18 males and 18 females) were assigned equally into three groups labeled as vehicle (10%  
Tween 20); 2 g/kg and 5 g/kg of BClHC in vehicle preparation, respectively. The animals were fasted 
overnight (food but not water) prior to dosing. Food was withheld for a further 3 to 4 hours after 
dosing. The animals were observed for 30 min and 2, 4, 24 and 48 hours after the administration for 
the onset of clinical or toxicological symptoms. Mortality, if any, was observed over a period  
of 2 weeks. The animals were sacrificed on the 15th day. Hematological, serum biochemical and 
histological (liver and kidney) parameters were determined following standard methods [46,47]. 
3.5. Treatment 
Gastric ulcer was induced in adult male Wistar rats by orogastric intubation of absolute ethanol  
(5 mL/kg) according to the method described by De Pasquale et al. [48] with slight modifications. 
Blank and ulcer control groups were orally administered with vehicle (10% Tween 20) solution. 
Experimental groups were orally administered with. 50, 100, 200 and 400 mg/kg of BClHC in vehicle 
solution (5 mL/kg), respectively. The positive group received oral doses of 20 mg/kg omeprazole in 
vehicle solution (5 mL/kg) as positive controls one hour after this pre-treatment; all groups of rats were 
gavaged with absolute ethanol (5 mL/kg) in order to induce gastric ulcers except the blank control 
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group which was only administered vehicle solution (5 mL/kg). The rats were euthanized by cervical 
dislocation 60 minutes later [49] under an overdose of diethyl ether anesthesia and their stomachs were 
immediately excised. 
3.6. Gross Gastric Lesions Evaluation 
Any ulcers would have be found in the gastric mucosa, appearing as elongated bands of 
hemorrhagic lesions parallel to the long axis of the stomach. Each gastric mucosa was thus examined 
for damage. The length (mm) and width (mm) of the ulcer on the gastric mucosa were measured by a 
planimeter (10 × 10 mm2 = ulcer area) under dissecting microscope (×1.8). The area of each ulcer 
lesion was measured by counting the number of small squares, 2 mm × 2 mm, covering the length and 
width of each ulcer band. The sum of the areas of all lesions for each stomach was applied in the 
calculation of the ulcer area (UA) wherein the sum of small squares × 4 × 1.8 = UA mm2 as described 
by Kauffman and Grossman [50] with slight modifications. The inhibition percentage (I%) was 
calculated using a slightly modified version of the formula described by Njar et al. [51]: 
(I%) = [(UAcontrol − UAtreated)/UAcontrol] × 100% 
3.7. Histological Evaluation of Gastric Lesions 
Specimens of the gastric walls from each rat were fixed in 10% buffered formalin and processed in 
a paraffin tissue processing machine. Sections of the stomach were made at a thickness of 5 µm and 
stained with hematoxylin and eosin for histological evaluation [52]. 
3.8. Study of Mucosal Glycoproteins 
Sections of 5 µm thickness of the glandular portion of the rat stomach of each group were stained 
with periodic acid Schiff (PAS) stain to observed mucus production and to note the changes in both 
acidic and basic glycoproteins [53]. 
3.9. Statistical Analysis 
All values were reported as means ± S.E.M. The statistical significance of differences between 
groups was assessed using one-way ANOVA. A value of p < 0.05 was considered significant. 
4. Conclusion 
BClHC could significantly protect the gastric mucosa against ethanol-induced injury. Such 
protection was shown to be dose dependent as ascertained by the reduction or inhibition of ulcer areas 
in the gastric wall as well as the reduction or inhibition of edema and leucocytes infiltration of 
submucosal layers, and protection was most prominent at a dose of 400 mg/kg BClHC. 
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